latest news releases from the newsroom
SmallCap Sentinel: The Breakthrough Deal
IRVINE, Calif., July 23, 2007 (PRIME NEWSWIRE) -- "In a market populated by bright-eyed companies with bold visions of market share and abundant success it is often difficult to discern those with staying power . . . and a real product line," stated SmallCap Sentinel analyst D.R. Clark. "But what can often indicate that a company indeed has the 'goods' is third-party validation by a well-known market leader. And a market leader offering its established credibility to an up-and-coming technology often precipitates an increase in revenues."
Grenville Gold Corp.
Photo Release -- Grenville Appoints CFO, CEO Featured On CEO Clips On The Biography Channel
VANCOUVER, British Columbia, July 23, 2007 (PRIME NEWSWIRE) -- Grenville Gold Corporation ("Grenville" or "the Company") (TSX-V:GVG) (Other OTC:GVLGF) (Frankfurt:F9I) (ISIN CA 3977181070/WKN:A0KELU) announces the appointment of Melvin Rokosh as the Chief Financial Officer. Grenville has received and accepted the resignation of Steven Brown, CFO and Director from Management and the Board.
BodyTel Scientific Inc.
BodyTel Scientific to Apply for CE Certification to Market `GlucoTel' throughout Europe
HENDERSON, Nev. and BAD WILDUNGEN, Germany, July 23, 2007 (PRIME NEWSWIRE) -- BodyTel Scientific Inc. (OTCBB:BDYT), a company focused on the development of innovative wireless healthcare products, today reported that it has begun the CE certification process for GlucoTel, a blood glucose monitoring device. The CE certification allows the company to market the GlucoTel monitoring device within the European Union and other countries using this standard. In order to assist in this certification process, CSL Cambridge Sensors Limited (www.cs-limited.co.uk), a designer and manufacturer of test strips for use in blood glucose test systems, has been retained.
MicroIslet Implements Staffing Changes to Further the Company's New Corporate Strategy
SAN DIEGO, July 23, 2007 (PRIME NEWSWIRE) -- As previously announced, MicroIslet, Inc. (OTCBB:MIIS) (the "Company") has refocused its efforts to accelerate the clinical testing of the Company's "MicroIslet-P(tm)" encapsulated islet preparation in persons suffering from Type 1 diabetes. In a first clinical phase, MicroIslet intends to initiate xenograft clinical trials in locations outside of the United States. As part of this strategy, the Company has recently implemented changes to both its management and Board of Directors. A second phase of this approach has now been initiated, and includes a shift in developmental expenditures and personnel. Accordingly, MicroIslet has decided to use outside facilities that operate under Good Manufacturing Practices (GMP) for islet isolation and encapsulation. These functions were previously performed in-house in non-GMP facilities, which was acceptable for preclinical development but not for human transplantation. MicroIslet also intends to refocus R&D efforts on finalizing its existing encapsulation technology for human transplantation. The Company is also exploring strategic partnership opportunities that may expedite and advance human clinical testing, both abroad and in the United States. The Company expects to make announcements regarding GMP facilities and other strategic partnerships later in the year. The current management and Board are extremely grateful to the employees who have made this a very smooth transition period.